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Human SAMHD1 (hSAMHD1) restricts HIV-1 infection in non-dividing cells by depleting intracellular
dNTPs to limit viral reverse transcription. Phosphorylation of hSAMHD1 at threonine (T) 592 by cyclin-
dependent kinase (CDK) 1 and CDK2 negatively regulates HIV-1 restriction. Mouse SAMHD1 (mSAMHD1)
restricts HIV-1 infection in non-dividing cells, but whether its phosphorylation regulates retroviral
restriction is unknown. Here we identiﬁed six phospho-sites of mSAMHD1, including T634 that is
homologous to T592 of hSAMHD1 and phosphorylated by CDK1 and CDK2. We found that wild-type
(WT) mSAMHD1 and a phospho-ablative mutant, but not a phospho-mimetic mutant, restricted HIV-1
infection in differentiated U937 cells. Murine leukemia virus (MLV) infection of dividing NIH3T3 cells was
modestly restricted by mSAMHD1 WT and phospho-mutants, but not by a dNTPase-defective mutant.
Our results suggest that phosphorylation of mSAMHD1 at T634 by CDK1/2 negatively regulates its HIV-1
restriction in differentiated cells, but does not affect its MLV restriction in dividing cells.
& 2015 Elsevier Inc. All rights reserved.Introduction
Sterile α motif (SAM) and HD domain containing protein 1
(SAMHD1) is a deoxynucleotide triphosphohydrolase (dNTPase)
(Goldstone et al., 2011; Powell et al., 2011) and functions as an
HIV-1 restriction factor in non-dividing myeloid cells and resting
CD4þ T cells (Baldauf et al., 2012; Hrecka et al., 2011; Laguette
et al., 2011a). Human SAMHD1 (hSAMHD1) inhibits infection of a
wide range of retroviruses including HIV-1 and murine leukemia
virus (MLV) (Gramberg et al., 2013), and DNA viruses, such as
herpes simplex virus type 1 in human macrophages (Kim et al.,
2013). The dNTPase activity of SAMHD1 enables it to decrease
intracellular dNTPs to below the levels required for retroviral
replication (Lahouassa et al., 2012), a general mechanism by which
hSAMHD1 impedes viral infection (Wu, 2013).esearch, The Ohio State Uni-
Tel.: þ1 614 292 5408.
apitola Drive, Durham, NCSAMHD1 is a conserved protein in humans and mice (Yang
et al., 2014). The mouse SAMHD1 gene contains two start codons,
and it is possible that both start codons are used for translation
in vivo. Alternative splicing of the mSAMHD1 pre-mRNA results in
two isoforms of the protein (isoform 1 and 2), which share 72%
and 74% protein sequence identities with hSAMHD1. Both
mSAMHD1 isoforms possess dNTPase activity (Lahouassa et al.,
2012; Powell et al., 2011; Zhang et al., 2014), and isoform 1 mRNA
is more abundantly expressed than isoform 2 mRNA in various
mouse tissues (Zhang et al., 2014). Compared to hSAMHD1 wild-
type (WT) or phospho-ablative mutants, phospho-mimetic
mutants at residue T592 lose their HIV-1 restriction phenotype
in non-dividing cells (Cribier et al., 2013; Pauls et al., 2014;
St Gelais et al., 2014; Welbourn et al., 2013; White et al., 2013b). It
has been proposed that T592 phosphorylation of hSAMHD1
negatively regulates its RNase activity in cells and may affect HIV-1
restriction (Ryoo et al., 2014). These studies suggest that T592
phosphorylation of hSAMHD1 plays a role in regulating its HIV-1
restriction function. However, there is no evidence linking the
phosphorylation of mSAMHD1 to its retroviral restriction
F. Wang et al. / Virology 487 (2016) 273–284274phenotype. It is also unknown whether mSAMHD1 and hSAMHD1
restrict HIV-1 and MLV through the same mechanism.
Here, we aim to elucidate the contribution of mSAMHD1
phosphorylation to its retroviral restriction function in cells. We
identiﬁed that T634 is a phosphosite of mSAMHD1 isoform 1 (refer
to as mSAMHD1 unless isoform 2 is indicated) and demonstrated
that CDK1 and CDK2 phosphorylate mSAMHD1 at T634 in dividing
cells. We examined the effect of T634 phosphorylation on
mSAMHD1-mediated restriction of HIV-1 or MLV in human and
mouse cell lines stably expressing mSAMHD1 WT, phospho-abla-
tive, phospho-mimetic or dNTPase-defective mutants. We found
that T634 phosphorylation of mSAMHD1 regulates its HIV-1
restriction in differentiated human U937 cells. In dividing mouse
NIH3T3 cells, overexpression of mSAMHD1 or hSAMHD1 modestly
restricts MLV infection, which is independent of T634 phosphor-
ylation of mSAMHD1. Our results demonstrate that phosphoryla-
tion of mSAMHD1 modulates its restriction of HIV-1 infection in
non-dividing cells, but not MLV infection in dividing cells, sug-
gesting different mechanisms of regulating retroviral restriction by
hSAMHD1 and mSAMHD1.Results
Identiﬁcation of phosphorylation sites of mSAMHD1 protein
Mouse SAMHD1 was identiﬁed as a phosphoprotein in previous
large-scale analyses of phosphorylated proteins (Sweet et al.,
2009; Villen et al., 2007; Zanivan et al., 2008). The C-terminal
protein sequences of human and mouse SAMHD1 are highly
conserved (Yang et al., 2014), and contain the residue T592 in
hSAMHD1 and a predicted phosphosite at position T634 in
mSAMHD1 isoform 1 with the ﬁrst start codon aligning with the
start codon of hSAMHD1 (Cribier et al., 2013; Villen et al., 2007). In
non-dividing cells, WT hSAMHD1 and a phospho-ablative mutant
(T592A) restrict HIV-1 infection, while phospho-mimetic mutants
of hSAMHD1 lose HIV-1 restriction (Cribier et al., 2013; Welbourn
et al., 2013; White et al., 2013b), suggesting that phosphorylation
negatively affects the HIV-1 restriction function of hSAMHD1. We
thus questioned whether phosphorylation at T634 could be a
negative regulatory mechanism for mSAMHD1-mediated restric-
tion of retroviral infection. Given that mSAMHD1 isoform 1 is
more abundantly expressed compared to isoform 2, in multiple
tissues (Zhang et al., 2014), we focused our study on mSAMHD1
isoform 1.
To identify phosphosites of mSAMHD1, tandem mass spectro-
metry (MS/MS) was performed with phosphorylation modiﬁcation
analysis after immunoprecipitation of full-length mSAMHD1 iso-
form 1 (St Gelais et al., 2014). A total of 678 peptides were assigned
to mSAMHD1 providing 72% coverage of the protein. Six phos-
phorylated residues were identiﬁed including threonines 52, 56,
310, and 634, and serines 55 and 140 (Table 1). Fig. 1 shows a
representative MS/MS spectrum for the peptide that allowed
identiﬁcation of T634 phosphorylation of mSAMHD1 isoform 1.
There were 36 peptides identiﬁed covering this region, of which 17Table 1
Mapping mouse SAMHD1 phosphorylation sites by mass spectrometry.
% Residues mapped a Phosphorylation sites b
Serines (S) 72% (26/36) S55, S140
Threonines (T) 83% (20/24) T52, T56, T310, T634
Total residues 72% (476/658) Indicated above
a The percentages of covered residues over total residue in MS/MS data.
b Residue positions of phosphorylated serines (S) and threonines (T) were
identiﬁed by MS/MS analysis.corresponded to phosphorylated T634, providing strong con-
ﬁdence in phospho-modiﬁcation of this residue. Interestingly,
based on sequence alignment of mSAMHD1 and hSAMHD1
(Fig. 2A), T634 is homologous to the known T592 phosphosite of
hSAMHD1 that negatively regulates hSAMHD1-mediated HIV-1
restriction (Cribier et al., 2013; St Gelais et al., 2014; Welbourn
et al., 2013; White et al., 2013b).
To conﬁrm the phosphorylation status of mSAMHD1 isoform
1 at T634 in cells, we generated a phospho-speciﬁc SAMHD1
antibody, whose epitope targets the consensus C-terminal
sequences of hSAMHD1 and mSAMHD1 encompassing the
phospho-sites T592 and T634. Thus, the antibody can speciﬁcally
detect T592 phosphorylated hSAMHD1 and T634 phosphorylated
mSAMHD1. We generated two mSAMHD1 isoform 1 mutants
substituting threonine with a phospho-ablative alanine residue
(T634A) or phospho-mimetic aspartic acid residue (T634D).
Transient overexpression of mSAMHD1 WT, T634A or T634D in
HEK293T cells was detected by immunoblotting. Total hSAMHD1
was detected at 72 kDa, while mSAMHD1 WT and mutants were
detected at 76 kDa, as expected (Fig. 2B). Phosphorylation of
hSAMHD1 at T592 and mSAMHD1 isoform 1 at T634 was detected
using the speciﬁc phospho-SAMHD1 antibody. As expected,
phospho-ablative and phospho-mimetic mutants of mSAMHD1
isoform 1 had no detectable signal when using the speciﬁc
phospho-SAMHD1 antibody (Fig. 2B). Moreover, to test whether
the endogenous mSAMHD1 is also phosphorylated, we performed
immunoblotting with lysates from mouse ﬁbroblast NIH3T3 cells
and mouse embryonic ﬁbroblasts (MEFs). Speciﬁc SAMHD1 bands
were detected in MEFs using a SAMHD1 antibody and a phospho-
SAMHD1 antibody (Fig. 2C), suggesting that endogenous
mSAMHD1 is also phosphorylated at T634 in primary mouse
ﬁbroblasts. In contrast, a very low level of endogenous mSAMHD1,
but not the T634 phosphorylated protein, was detected in NIH3T3
cells (Fig. 2C), which might be due to detection limit of the
phospho-SAMHD1 antibody.
CDK1 and CDK2 contribute to T634 phosphorylation of mSAMHD1 in
HEK293T cells
The CDK1/CDK2 and cyclin A2 complex phosphorylates
hSAMHD1 at position T592 in dividing cells (Cribier et al., 2013;
Pauls et al., 2014; St Gelais et al., 2014; White et al., 2013b). Our
previous results showed that both hSAMHD1 and mSAMHD1
interact with CDK1 and CDK2 in HEK293T cells (St Gelais et al.,
2014). Similar to T592 in hSAMHD1, T634 of mSAMHD1 is located
within a predicted CDK-binding motif, TPXK (Cribier et al., 2013)
(Fig. 2A); therefore, it is possible that CDK1 and CDK2 could be
responsible for the phosphorylation of mSAMHD1 at T634.
To determine whether CDK1 and CDK2 contribute to phos-
phorylation of mSAMHD1 at T634, we ﬁrst inhibited the kinase
activities of CDK1 and CDK2 using speciﬁc inhibitors. HEK293T
cells were pretreated with speciﬁc inhibitors for 6 h, and trans-
fected to transiently express mSAMHD1 WT. Cell lysates were
collected 24 h post-transfection and used for immunoblotting to
determine the levels of total and phospho-SAMHD1. To evaluate
changes in the level of phospho-mSAMHD1, the relative level of
phospho/total mSAMHD1 was calculated after GAPDH normal-
ization based on densitometry analysis of these protein bands.
Compared to control cells treated with DMSO, individual and
combined treatments with inhibitors to CDK1 and CDK2 reduced
the relative levels of phospho-mSAMHD1 by 62% (P o0.01), 34%
(P o0.05), and 66% (P o0.01), respectively (Fig. 3A and B). These
results suggest that both CDK1 and CDK2 phosphorylate
mSAMHD1 at T634 in dividing human cells.
To exclude the potential off-target effect of using speciﬁc
inhibitors to CDK1 and CDK2, we also used well-characterized
Fig. 1. Residue T634 in the mSAMHD1 protein sequence is a phosphosite as identiﬁed by tandem mass spectrometry. Position T634 was identiﬁed as a phosphosite by MS/
MS analysis. An example MS/MS spectrum is shown for the indicated tryptic peptide of mSAMHD1 (residues 619 to 637) that identiﬁed the T634 phosphorylation site, which
is highlighted in the sequence and denoted by a “(p)”. Assigned b ions are shown in red, and y ions are shown in blue. Green peaks represent loss of a 98 Da fragment that
corresponds to loss of a phosphate group as indicated.
Fig. 2. Conﬁrmation of the phosphorylation of mSAMHD1 at position T634 using a phospho-speciﬁc antibody. (A) Partial protein sequence alignment of mSAMHD1 isoform
1 and human (hSAMHD1) depicting conserved phosphosites at residue positions T634 and T592 in mSAMHD1 and hSAMHD1 sequences, respectively. The phosphorylated
residue threonine (T) is underlined and the residues encompassing a consensus sequence (TPXK) for CDK interaction are highlighted in bold. (B) HEK293T cells were
transiently transfected to overexpress hSAMHD1, mSAMHD1 wild-type (WT), phospho-ablative mutant (T634A) or phospho-mimetic mutant (T634D). Immunoblotting was
performed on cell lysates to conﬁrm position T634 of mSAMHD1 is a phosphosite. Total SAMHD1 protein levels were probed using an anti-HA antibody (top panel).
(C) Endogenous mSAMHD1 in mouse embryonic ﬁbroblasts (MEFs) is phosphorylated at T634. The total SAMHD1 was probed with a speciﬁc SAMHD1 antibody. (B) and
(C) The phospho-SAMHD1 levels were detected using a phospho-speciﬁc SAMHD1 antibody (middle panel). GAPDH was used as a loading control. A representative
immunoblot result from three independent experiments is shown.
F. Wang et al. / Virology 487 (2016) 273–284 275dominant negative (DN) mutants of CDK1 and CDK2 (van den
Heuvel and Harlow, 1993) to abolish their kinase activities.
HEK293T cells were transiently transfected to express mSAMHD1
WT together with WT or dominant negative (DN) mutants of CDK1
or CDK2. Overexpression of hemagglutinin (HA)-tagged CDK1 or
CDK2 was conﬁrmed by immunoblotting. The levels of total and
phospho-mSAMHD1 were conﬁrmed and quantiﬁed by densito-
metry analysis of these protein bands (Fig. 3C). Summarized
results of three independent experiments are presented in Fig. 3D.
We found that the level of phospho-mSAMHD1 was reduced by
25% in cells overexpressing CDK1 DN compared to CDK1 WT.
Interestingly, when we compared cells overexpressing CDK2 DN to
CDK2 WT, the CDK2 DN exhibited a much stronger effect and the
level of phospho-mSAMHD1 was reduced by 84% (P o0.05)
(Fig. 3D). These results suggest that both CDK1 and CDK2 con-
tribute to T634 phosphorylation of mSAMHD1 in dividing cells and
that CDK2 likely plays a more important role than CDK1.
To conﬁrm that endogenous CDK1 and CDK2 contribute to
phosphorylate mSAMHD1 at T634 in HEK293T cells, we usedspeciﬁc siRNA mediated knockdown (KD) of CDK1 and CDK2 as an
alternative method. After two rounds of siRNA transfections, we
effectively reduced the expression of CDK1 by approximately 95%
and CDK2 by 73% in HEK293T cells (Fig. 3E). Compared to control
cells transfected with non-speciﬁc siRNA, knockdown of CDK1 and
CDK2 decreased the relative levels of phospho-mSAMHD1 by 54%
and 60%, respectively (Fig. 3F). When CDK1 and CDK2 were
knocked down together, the relative level of phospho-mSAMHD1
was reduced by 73% (Po0.05) (Fig. 3F), suggesting a synergistic or
additive effect of the double KD. Using three different approaches,
we further conﬁrmed that CDK1 and CDK2 contribute to phos-
phorylation of mSAMHD1 at T634.
Endogenous CDK1 and CDK2 phosphorylate mSAMHD1 at T634 in
mouse ﬁbroblast cells
Because CDK1 and CDK2 are highly conserved in human and
mice (Malumbres and Barbacid, 2005) and share 97% and 85%
amino acid identity, respectively, it is expected that mSAMHD1
Fig. 3. CDK1 and CDK2 contribute to T634 phosphorylation of mSAMHD1 in HEK293T cells. (A) Cells were pre-treated with DMSO or inhibitors speciﬁc to CDK1 or CDK2 at
1 mM for 6 h and transiently transfected to overexpress mSAMHD1. The effect of each inhibitor on the phosphorylation of mSAMHD1 at T634 was assessed at 24 h post-
transfection by immunoblotting. (B) An average of three independent experiments described in (A). (C) mSAMHD1 was overexpressed together with wild-type (WT) or
dominant negative (DN) mutants of CDK1 or CDK2. Empty vector was used as a negative control. At 24 h post-transfection, cells were harvested for immunoblotting to
determine total SAMHD1, phosphorylated SAMHD1 and CDK expression levels. Total mSAMHD1 and CDK1/2 protein levels were detected using an HA-speciﬁc antibody and
phosphorylation of T634 was detected using a phospho-speciﬁc SAMHD1 antibody. (D) An average of three independent experiments described in (C). (E) Individual and
combined siRNA-mediated knockdown of endogenous CDK1 and CDK2 were performed in the presence of ectopically expressed mSAMHD1 using a two-round transfection
protocol. Cells were harvested 24 h following the second round of siRNA transfection and cell lysates were subjected to immunoblotting to determine the effect of CDK1/2
knockdown on the phosphorylation of mSAMHD1 at T634. The efﬁciency of siRNA-mediated knockdown of CDK1 and CDK2 was determined by probing with their respective
antibodies. (F) An average of three independent experiments described in (E). In (A, C and E), total SAMHD1 levels were detected using an HA-speciﬁc antibody. The levels of
phospho-SAMHD1 were detected using a phospho-SAMHD1 speciﬁc antibody. GAPDH was used as a loading control. In (B, D and F), the protein levels were quantiﬁed based
on the band densities. The levels of total mSAMHD1 and phospho-SAMHD1 were normalized to GAPDH respectively, and then the ratio of phospho/total mSAMHD1 was
calculated and the ratio of the vector group was set as 1. Results are shown as mean7SD (n¼3). The data was analyzed by T-test or one-way ANOVA with Dunnett’s test (*,
Po0.05, **, Po0.01).
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To validate whether endogenous CDK1 and CDK2 phosphorylate
mSAMHD1 at T634 in dividing mouse cells, murine ﬁbroblast
NIH3T3 cells lacking a high level of endogenous mSAMHD1 were
transduced to stably express mSAMHD1. These transduced NIH3T3cells were treated with inhibitors speciﬁc to CDK1 or CDK2. To
avoid cytotoxicity of the inhibitors, cell viability was tested in the
presence of the inhibitors at different concentrations (0.1–1.0 mM).
Based on the titration results and our previous published results
(St Gelais et al., 2014), cells were treated with 0.1 or 0.5 mM of the
Fig. 4. Endogenous CDK1 and CDK2 phosphorylate mSAMHD1 at T634 in mouse
ﬁbroblast cells. (A) NIH3T3 cells stably expressing mSAMHD1 were treated with
inhibitors speciﬁc to CDK1 or CDK2 at the indicated concentrations. The effects of
each inhibitor on the phosphorylation of mSAMHD1 at T634 were assessed at 24 h
post-transfection by immunoblotting with a phospho-speciﬁc antibody. (B) An
average of three independent experiments. The protein levels were quantiﬁed
based on the band densities. The levels of total mSAMHD1 and phospho-SAMHD1
were normalized to GAPDH, and then the ratio of phospho/total mSAMHD1 was
calculated and the ratio of the vector group was set as 100%. Results are shown as
mean7SD (n¼3). The data was analyzed by one-way ANOVA with Dunnett’s test
(*, Po0.05).
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level of total and phospho-mSAMHD1 was conﬁrmed by immu-
noblotting (Fig. 4A). Individual and combined treatments using
0.1 mM CDK1 and CDK2 inhibitors reduced the relative levels of
phospho-mSAMHD1 by approximately 2-fold compared to control
cells treated with DMSO (Fig. 4A and B). Utilizing a higher con-
centration of 0.5 mM, individually or in combination, reduced the
relative levels of phospho-mSAMHD1 by 45% (P 40.05), 78% (P
o0.05), and 83% (P o0.05) compared to DMSO treatment (Fig. 4A
and B). These results conﬁrm that endogenous CDK1 and CDK2
contribute to T634 phosphorylation of mSAMHD1 in mouse
dividing cells.
The effect of T634 phosphorylation of mSAMHD1 on restriction of
HIV-1 infection in differentiated U937 cells
Previous studies reported that mSAMHD1 restricts HIV-1
infection in non-dividing cells (Hofmann et al., 2012; Lahouassa
et al., 2012). Because T634 of mSAMHD1 is a conﬁrmed phos-
phosite that is homologous to T592 of hSAMHD1, and hSAMHD1-
mediated HIV-1 restriction can be negatively regulated by T592
phosphorylation in non-dividing cells (Cribier et al., 2013; Wel-
bourn et al., 2013; White et al., 2013b), it is conceivable that T634
phosphorylation also negatively regulates mSAMHD1-mediated
HIV-1 restriction in non-dividing cells. We thus sought to exam-
ine the importance of T634 phosphorylation in regulating
mSAMHD1-mediated HIV-1 restriction in a non-dividing cell
model. Using the lentiviral vectors previous described (Hofmann
et al., 2012; St Gelais et al., 2014), we generated human U937 cell
lines that stably express mSAMHD1 isoform 1WT, the T634phospho-mutants, or isoform 2WT that lacks the T634 phos-
phorylation at the C-terminus (Fig. 5A); hSAMHD1 WT was used
as a positive control for HIV-1 restriction (Welbourn et al., 2013;
White et al., 2013b). We conﬁrmed comparable expression levels
of SAMHD1 WT or mutant in non-dividing U937 cells differ-
entiated with phorbol 12-myristate 13-acetate (PMA) (Fig. 5B).
To investigate the effect of T634 phosphorylation of mSAMHD1
on its HIV-1 restriction, we performed single-cycle HIV-1 infection
of U937 cells expressing SAMHD1 WT and mutants after PMA
differentiation. HIV-1 infection was measured at 24 h post-
infection. We observed HIV-1 restriction in cells expressing WT
hSAMHD1, WT mSAMHD1 isoform1 or T634A mutant, and WT
mSAMHD1 isoform 2, but not in cells expressing the phospho-
mimetic mutants of mSAMHD1 isoform1 (T634D) compared to
vector control cells (Fig. 5C). Our data suggest a negative regula-
tion of HIV-1 restriction by T634 phosphorylation of mSAMHD1,
which is consistent with the effect of T592 phosphorylation
on hSAMHD1-mediated HIV-1 restriction (Cribier et al., 2013;
Gramberg et al., 2013; Hofmann et al., 2012; St Gelais et al., 2014;
Welbourn et al., 2013; White et al., 2013b).
To verify whether HIV-1 restriction by mSAMHD1 WT or
mutants in PMA-differentiated U937 cells was due to a reduced
dNTP pool, the intracellular dNTP levels were measured using the
single nucleotide incorporation assay (St Gelais et al., 2012).
Compared to PMA-differentiated vector control U937 cells, the
intracellular dNTP levels in cells expressing mSAMHD1 WT or
mutants were reduced 2- to 6-fold (Po0.0001) (Fig. 5C). The dNTP
levels were comparable among the cells expressing WT hSAMHD1,
WT or mutant mSAMHD1 isoform 1, and WT mSAMHD1 isoform 2
(Fig. 5D), suggesting that T634 phosphorylation of mSAMHD1 does
not signiﬁcantly affect its dNTPase function in cells. Our data are
consistent with published results that the dNTPase activity of
hSAMHD1 is not regulated by its T592 phosphorylation in non-
dividing cells (White et al., 2013b).
MLV infection in NIH3T3 cells is reduced by mSAMHD1 independently
of its T634 phosphorylation
Knockdown of mSAMHD1 expression in mouse macrophage-
like cells relieves SAMHD1’s restriction of MLV infection (Zhang
et al., 2014). However, whether T634 phosphorylation of
mSAMHD1 regulates MLV infection restriction is unknown. To test
the importance of T634 phosphorylation in regulating mSAMHD1-
mediated MLV restriction, we generated mouse ﬁbroblast cells
lines (NIH3T3) that stably express mSAMHD1 isoform1 WT, T634A
or T634D mutant, or mSAMHD1 isoform 2. Human SAMHD1 WT
and a phospho-ablative mutant (T592A) were included as controls
(St Gelais et al., 2014). Comparable expression levels of SAMHD1
WT and mutants in dividing NIH3T3 cells were conﬁrmed by
immunoblotting (Fig. 6A). As expected, phosphorylated hSAMHD1
or mSAMHD1 was only detected in cells expressing WT hSAMHD1
and WT or the HD/AA mutant of mSAMHD1 isoform 1, but not the
phospho-mutants or mSAMHD1 isoform 2 using the speciﬁc
phospho-SAMHD1 antibody (Fig. 6A). Next, NIH3T3 cells stably
expressing SAMHD1 WT or mutants were infected with a single-
cycle GFP reporter MLV and GFP-positive cells were quantiﬁed by
ﬂow cytometry at 48 h post-infection. Interestingly, the percen-
tage of GFP-positive cells was reduced by 8.815.8% in cells
expressing SAMHD1 WT and phospho-mutants (Po0.0001)
compared to that in vector control cells (Fig. 6B). These results
suggest that restriction of MLV infection in dividing cells by
mSAMHD1 is independent of its T634 phosphorylation.
To discriminate whether mSAMHD1 speciﬁcally restricts MLV
in NIH3T3 cells, we also tested HIV-1 infection in NIH3T3 cells
expressing WT hSAMHD1, mSAMHD1 isoform 1, or mSAMHD1
isoform 2. Cells were infected with HIV-1 GFP/VSV-G reporter
Fig. 5. The effect of T634 phosphorylation of mSAMHD1 on its restriction of HIV-1 infection in PMA-differentiated U937 cells. (A) The C-terminus alignment of mSAMHD1
isoform 1 (iso1) and isoform 2 (iso2) proteins illustrating the T634 region is lacking in the iso2 protein. (B) The expression levels of total and phosphorylated SAMHD1 (WT
and mutants) in U937 stable cell lines were determined by immunoblotting with an anti-HA antibody and speciﬁc phospho-SAMHD1 antibody, respectively. GAPDH was
used as a loading control. (C) U937 cells expressing hSAMHD1 WT, mSAMHD1 WT, phospho-ablative mutant (T634A), phospho-mimetic mutant (T634D) or an empty vector
were infected with a single-cycle HIV-1 luc/VSV-G at a multiplicity of infection (MOI¼1). At 24 h post-infection, cells were harvested for luciferase assay to measure HIV-1
infection. An average of three independent infection experiments is presented (n¼12). The infection level in the vector control group was set as 100% for normalization.
(D) The levels of intracellular dNTPs were signiﬁcantly decreased by hSAMHD1, mSAMHD1 WT or mutants compared to the vector control (Po0.0001). The results are
shown as mean7SD (n ¼2). The dNTP concentrations were calculated based on the cell volume of human primary macrophages (2660 mm3). For (C and D), statistical
analysis was performed by one-way ANOVA and Dunnett’s test (***, Po0.0001).
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48 h post-infection. The HIV-1 infection levels did not differ
among cell lines expressing WT hSAMHD1, mSAMHD1 isoform 1,
or mSAMHD1 isoform 2, compared to vector control cells (Fig. 6C).
Thus, HIV-1 infection was not affected by overexpression of WT
hSAMHD1, mSAMHD1 isoform1 or isoform 2 in NIH3T3 cells.
To examine whether SAMHD1 inhibited MLV infection in
NIH3T3 cells by depleting cellar dNTPs to limit the completion of
viral reverse transcription products, we measured intracellular
dNTP levels in NIH3T3 cells stably expressing SAMHD1 WT and
mutants. In four independent experiments, we observed that dCTP
levels were signiﬁcantly reduced up to 2-fold in NIH3T3 cells
expressing SAMHD1 WT or phospho-mutants compared to vector
control cells (Fig. 6D), while all the other dNTPs were not sig-
niﬁcantly affected by SAMHD1 (data not shown). These data sug-
gest that mSAMHD1 WT or phospho-mutants likely maintain a
dNTPase activity, but may not signiﬁcantly reduce the high levels
of dNTPs in dividing NIH3T3 cells. These results are consistent
with our previous published data that overexpression of
hSAMHD1 in dividing HEK293T cells did not signiﬁcantly reduce
the intracellular dNTP pool (St Gelais et al., 2012).To assess whether the modest reduction of the dCTP levels by
mSAMHD1 is required for its inhibition of MLV infection in
dividing NIH3T3 cells, we generated a dNTPase-defective
mSAMHD1 mutant H238A/D239A (HD/AA). This mSAMHD1
mutant is homologous to the dNTPase-defective mutant H206A/
D207A of hSAMHD1, which does not restrict HIV-1 infection in
non-dividing cells (Laguette et al., 2011b; White et al., 2013a).
After conﬁrmation of comparable expression levels of mSAMHD1
WT and HD/AA mutant in NIH3T3 cells by immunoblotting
(Fig. 6A), cells were infected with a single-cycle GFP reporter MLV.
Interesting, mSAMHD1 HD/AA mutant did not restrict MLV infec-
tion compared to that in vector control cells (Fig. 6B), suggesting
that the dNTPase function of mSAMHD1 is required for its MLV
restriction.
MLV restriction by SAMHD1 in NIH3T3 cells is correlated with
reduced nuclear import of viral cDNA
To examine the mechanisms of MLV restriction by mSAMHD1,
we measured the levels of late reverse transcription products in
MLV-infected NIH3T3 cells by quantitative PCR. We ﬁrst veriﬁed
GFP-reporter MLV infection and SAMHD1-mediated MLV restriction
Fig. 6. MLV infection in dividing NIH3T3 cells is reduced by mSAMHD1 independently of its T634 phosphorylation. (A) Overexpression of HA-tagged mSAMHD1 isoform 1
(iso1) and isoform 2 (iso2) proteins and iso1 mutants in NIH3T3 stable cells lines was conﬁrmed by immunoblotting using anti-HA antibody. Vector-transduced cells were
used as a negative control. Phosphorylation status of hSAMHD1 (T592) and mSAMHD1 (T634) was assessed using a phospho-speciﬁc antibody. GAPDH was used as a loading
control. (B) Overexpression of SAMHD1 WT or iso1 phospho-mutants, but not the dNTPase-defective mSAMHD1 iso1 mutant H238A/D239A (HD/AA), in NIH3T3 cells
modestly reduces MLV infection. (C) HIV-1 infection is not restricted by WT hSAMHD1, WT mSAMHD1 iso1, or WT mSAMHD1 iso2 in NIH3T3 cells. NIH3T3 cells were
infected with a single-cycle MLV-GFP/VSV-G reporter virus (B) or an HIV-1-GFP/VSV-G reporter virus (C) (MOI¼1). At 48 h post-infection, cells were harvested to determine
the percentage of GFP-positive cells by ﬂow cytometry. (D) Intracellular dCTP levels were reduced in NIH3T3 cells expressing WT hSAMHD1, WT mSAMHD1 or phospho-
mutants of mSAMHD1. The concentrations calculated based on the average cell size of NIH3T3 (diameter is 18 mm) and the spherical cell assumption. The data were analyzed
by one-way ANOVA and Dunnett’s test (*, Po0.05, **, Po0.01, ***, Po0.0001).
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transcriptase inhibitor azidothymidine (AZT) was used to inhibit
reverse transcription, which caused the percentage of GFP-positive
cells to signiﬁcantly reduce to less than 5%, in vector control and
SAMHD1-expressing cell lines (Fig. 7A and D). The results from
three independent experiments showed no statistical difference
between the levels of MLV late reverse transcription products in
cells expressing SAMHD1 WT, phospho-mutants or the dNTPase
defective mutant relative to that in vector control cells (Fig. 7B and
E), suggesting that MLV reverse transcription is not affected by
SAMHD1 and its T634 phosphorylation in NIH3T3 cells. Asexpected, AZT treatment signiﬁcantly decreased late reverse tran-
scription products by approximately 2.2- to 8-fold in the infected
cells (Po0.05) (Fig. 7B and E).
To assess whether SAMHD1 expression in NIH3T3 cells affected
the MLV life cycle at the stage after reverse transcription, we
evaluated the levels of MLV 2-LTR circles in the infected cells,
which is a surrogate marker for nuclear import of MLV cDNA
(Yamashita and Emerman, 2005). The levels of 2-LTR circles in cells
expressing SAMHD1 WT or phospho-mutants were reduced by
35.8–52.4% (Po0.01) compared to that in vector control cells, but
were not affected by mSAMHD1 HD/AA mutant (Fig. 7C and 7F),
Fig. 7. MLV infection in dividing NIH3T3 cells is inhibited by mSAMHD1 at the viral cDNA nuclear import stage but not the late RT step. (A and D) MLV infection in cells
expressing WT or mutant SAMHD1 was reduced by AZT treatment (5 mM). (B and E) The levels of late reverse transcription (RT) products in MLV infected cells were not
affected by overexpression of SAMHD1 WT or mutants in NIH3T3 cells. (C and F) The levels of 2-LTR circles were reduced by overexpression of SAMHD1 WT or phospho-
mutants in NIH3T3 cells, the AZT treatment, but not overexpression of the HD/AA mutant of mSAMHD1 isoform 1 (iso1). (A–F) Cells were infected with MLV-GFP/VSV-G
(MOI¼1) in the presence of control media or AZT (5 mM). Cells were harvested at 24 h post-infection and used for genomic DNA extraction. The levels of MLV late RT
products (B and E) and of 2-LTR circles (C and F) were measured using real-time PCR. An average of three independent experiments was presented. After normalization to
GAPDH, the levels of late reverse transcription products or 2-LTR circles in MLV-infected vector control cells were set as 100%. The data were analyzed by one-way ANOVA
and Dunnett’s test (*, Po0.05, **, Po0.01, ***, Po0.0001).
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in NIH3T3 cells. These results suggest that mSAMHD1 and
hSAMHD1 can moderately restrict MLV infection in dividing
mouse cells by limiting the nuclear import of viral cDNA, inde-
pendent of phosphorylation of SAMHD1.
Discussion
In this study, we identiﬁed and conﬁrmed that T634 of
mSAMHD1 is phosphorylated by CDK1 and CDK2 in cells. Ourresults indicate that restriction of HIV-1 infection by mSAMHD1 in
non-dividing cells is regulated through its T634 phosphorylation.
In contrast, MLV infection in dividing cells is restricted by
mSAMHD1 or hSAMHD1 at the stage of viral cDNA nuclear import,
which appears to require dNTPase activity, but is independent of
T634 phosphorylation.
In addition to T634, we identiﬁed ﬁve other phosphosites in
mSAMHD1 (Table 1). Whether these additional phosphosites
regulate the mSAMHD1-mediated restriction of HIV-1 or MLV
F. Wang et al. / Virology 487 (2016) 273–284 281infection remain to be investigated. Further analysis of these other
phosphosites may help to understand the mechanism by which
mSAMHD1 restricts retroviral infection in dividing cells.
We found that both CDK1 and CDK2 contribute to T634 phos-
phorylation of mSAMHD1, which is in agreement with data that
hSAMHD1 T592 is mainly phosphorylated by CDK1 and CDK2
(Cribier et al., 2013; Pauls et al., 2014; St Gelais et al., 2014; White
et al., 2013b). The relative importance of CDK1 and CDK2 in
phosphorylating mSAMHD1 at T634 residue in dividing cells
appears different when we used distinct approaches, including
speciﬁc inhibitors, DN mutants, and siRNA to CDK1 or CDK2
(Fig. 3). This discrepancy could be due to different efﬁciencies or
effects in inhibiting the activities or expression levels of CDK1 and
CDK2 using distinct reagents and methods.
As CDK1 and CDK2 are highly conserved between human and
mouse, we also conﬁrmed that endogenous mouse CDK1 and
CDK2 contributed to T634 phosphorylation of mSAMHD1. Our data
showed that residual phosphorylated hSAMHD1 (T592) and
mSAMHD1 (T634) were detectable in PMA-differentiated non-
dividing U937 cells, possibly due to expression of CDK2, which
unlike CDK1, is not decreased upon PMA-differentiation (St Gelais
et al., 2014).
Both hSAMHD1 WT and a phospho-ablative mutant restrict
HIV-1 infection in differentiated U937 cells, while phospho-
mimetic mutants of hSAMHD1 lose the restriction of HIV-1
infection (Welbourn et al., 2013; White et al., 2013b). In our
study, we found that WT hSAMHD1, WT and a phospho-ablative
mutant (T634A) mSAMHD1 isoform 1, as well as WT mSAMHD1
isoform 2 lacking the T634 phosphorylation site, restricted HIV-1
infection in non-dividing cells, while a phospho-mimetic mutant
of mSAMHD1 isoform 1 (T634D) lost restriction of HIV-1 infection
in U937 cells. Overall, these results indicate that phosphorylation
of mSAMHD1 isoform 1 at T634 also negatively regulates its
restriction of HIV-1 infection.
We showed that phosphorylation of mSAMHD1 at T634 does
not change its ability to reduce the dNTP pool in differentiated
U937 cells, which is consistent with earlier reports that phos-
phorylation of hSAMHD1 does not alter its dNTPase activity in
cells (Welbourn et al., 2013; White et al., 2013b). However, a recent
study using in vitro assays showed impaired dNTPase activity of
the phospho-mimetic mutation T592E compared to WT hSAMHD1
(Tang et al., 2015). This discrepancy might be due to different
assays used in these studies. Moreover, the intracellular dNTP
levels at one single time point were measured and used as an
indicator of the dNTPase activity of SAMHD1 in cells (Welbourn
et al., 2013; White et al., 2013b). It is also possible that, even with a
decreased dNTPase activity, phospho-mimetic mutants of
SAMHD1 may still be able to reduce the intracellular dNTP levels
similarly compared to WT SAMHD1.
Non-dividing cells are refractory to MLV infection mainly
because of limited nuclear import of MLV cDNA (Yamashita and
Emerman, 2005). Therefore, we used a dividing mouse cell model
to test SAMHD1’s restriction of MLV infection. Our results suggest
that MLV infection of dividing mouse cells can be inhibited by
hSAMHD1 and mSAMHD1 at the stage of viral cDNA nuclear
import, which is independent of T634 phosphorylation, but
requires dNTPase function of SAMHD1. In contrast to MLV inhibi-
tion, we also observed that overexpression of WT hSAMHD1,
mSAMHD1 isoform 1 or isoform 2 in dividing NIH3T3 cells did not
affect HIV-1 infection. Given that SAMHD1 acts as a dNTPase in
dividing cells, it is possible that overexpression of SAMHD1 can
affect cell proliferation or cell cycle progression, thereby resulting
in impeded MLV cDNA nuclear import and infection. Therefore,
depletion of cellular dNTPs by SAMHD1 might have a restrictive
effect on retroviral infection through other mechanisms in addi-
tion to blocking completion of viral reverse transcription.Of note, conﬂicting results on the effect of mSAMHD1 on MLV
infection have been reported. MLV infection is increased approxi-
mately 2-fold in a mouse macrophage cell line after mSAMHD1
knockdown compared to control cells (Zhang et al., 2014). In
contrast, MLV infection was not affected in cells from SAMHD1-
deﬁcient mice relative to cells from WT mice (Behrendt et al.,
2013; Rehwinkel et al., 2013). Differences in cell type and experi-
mental approaches used could be confounding factors that lead to
the inconsistent MLV restriction by mSAMHD1.
In summary, we identiﬁed six phosphosites in mSAMHD1 and
demonstrated that CDK1 and CDK2 phosphorylate T634 of
mSAMHD1 in dividing cells. T634 phosphorylation of mSAMHD1
regulate restriction of HIV-1 infection in non-dividing cells, but not
MLV infection in dividing cells, suggesting different mechanisms of
regulating retroviral restriction by hSAMHD1 and mSAMHD1.Materials and methods
Plasmids
The plasmids encoding hemagglutinin (HA)-hSAMHD1, HA-
mSAMHD1 isoform 1 and empty vectors (Lahouassa et al., 2012)
were kind gifts from Dr. Nathaniel Landau (New York University).
Plasmids expressing HA-tagged mutant mSAMHD1 isoform 1 were
generated using a Quickchange mutagenesis kit (Agilent Technol-
ogies) according to manufacturer’s protocol. To generate
mSAMHD1 T634A and T634D mutants, the following two primers
were used, respectively: 5’- GCT CCA CTC ATA GCC CCT CTG AAA
TGG -3’ and 5’- GCT CCA CTC ATA GAC CCT CTG AAATGG -3’. The
plasmids expressing HA-tagged WT or dominant negative (DN)
mutant of CDK1 or CDK2 (van den Heuvel and Harlow, 1993) were
purchased from Addgene.
Cell culture and generating stable cell lines expressing SAMHD1
Human embryonic kidney 293T (HEK293T) cells and a HIV-1
reporter cell line GHOST/X4/R5 have been described (Wu et al.,
2002a; Wu et al., 2002b). Monocytic U937 cells lines were main-
tained as described (de Silva et al., 2013; Wang et al., 2007). U937
cells stably expressing WT hSAMHD1, WT mSAMHD1, or mutant
mSAMHD1 (T634A or T634D) were generated by spinoculation of
U937 cells with concentrated lentiviral vectors, and then cultured
with 0.8 μg/mL puromycin containing media for selection as
described (Hofmann et al., 2012; St Gelais et al., 2014). NIH3T3 cells
were transduced with lentiviral vectors expressing hSAMHD1,
mSAMHD1 WT or mutants for 2 h, and then cultured with 2 μg/mL
puromycin containing media (DMEM with 10% fetal bovine serum,
and 1% penicillin and streptomycin) 48 h after the transduction.
MEFs were maintained in DMEM with 10% fetal bovine serum, and
1% penicillin and streptomycin as described (Shembade et al., 2007).
Transfections of HEK293T cells
To produce lenti-viral vectors expressing hSAMHD1, mSAMHD1
WT, mSAMHD1 mutants or vector control, HEK293T cells were
seeded at 3105 cells/well in 6-well plates. After 24 h, cells were
transfected using a calcium phosphate method as described (St
Gelais et al., 2014). To express WT or DN mutants of CDK1 or CDK2
in HEK293T cells, cells were seeded at 2105 cells/well in 12-well
plates. Plasmids encoding WT or DN mutant CDK1 or CDK2, or
empty vectors (0.75 μg for each) were co-transfected with plenti-
HA-mSAMHD1 vector (0.25 μg) as described (St Gelais et al., 2014).
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Cells were harvested at 24 h after transfection, and lysed with
cell lysis buffer (Cell Signaling) containing protease inhibitor
cocktail (Sigma-Aldrich). Cell lysates were prepared for immuno-
blotting (Janas and Wu, 2009) and the blots were detected using
antibodies speciﬁc against HA (Covance, Ha.11 clone 16B12),
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (AbD ser-
otec), CDK1 (Cell signaling, #9112), CDK2 (Santa Cruz, sc-163),
SAMHD1 (Prosci, No.1224). Rabbit antibodies speciﬁc for phospho-
SAMHD1 were generated by ProSci Inc. using phosphorylated
hSAMHD1 peptide (Cribier et al., 2013): FTKPQDGDVIAPLI(Tp)
PQKKE. The phospho-speciﬁc antibody was sequentially afﬁnity-
puriﬁed from the rabbit sera with a non-phospho-peptide con-
jugated column and a phospho-peptide conjugated column.
Immunoblotting images were obtained and analyzed using Lumi-
nescent Image analyzer (LAS 4000) and Mutil-Gauge V3.0 software
(Fuji Film) as described (St Gelais et al., 2012).
Mass spectrometry
HEK293T cells were transfected to express HA-tagged
mSAMHD1 and prepared for mass spectrometry as described (St
Gelais et al., 2014). Peptides were analyzed at the Ohio State
University Mass Spectrometry Core Facility using an LTQ-Orbitrap
mass spectrometer. Tandem mass spectrometry samples were
analyzed using Mascot (Matrix Science, version 2.4.1). Mascot was
set up to search the SwissProt_ID_2013_02 database (selected for
Mus musculus) assuming the digestion enzyme trypsin. Mascot
was searched with a fragment ion mass tolerance of 0.80 Da and a
parent ion tolerance of 20 PPM. Phosphorylation of serine, threo-
nine and tyrosine were speciﬁed in Mascot as variable modiﬁca-
tions. Analysis of identiﬁed peptides and phosphorylated residues
was performed using Scaffold software with a minimum protein
probability of 99.0% and minimum peptide probability of 95%
(Proteome Software Inc.).
Treatment of cells with CDK1 and CDK2 inhibitors
HEK293T cells were pre-treated with speciﬁc inhibitors to
CDK1 (Cribier et al., 2013) (CGP74513A, EMD Milliproe), CDK2
(Bramson et al., 2001) (Inhibitor II, Santa Cruz Biotech) at 1 μM, or
dimethyl sulfoxide (DMSO) (Sigma-Aldrich) for 6 h. Cells were
transfected with plenti-HA-mSAHMD1 to express mSAMHD1 WT.
The inhibitors were present during transfection, and at 12 h post-
transfection fresh media with inhibitors were added. Cells were
harvested at 24 h post-transfection, and processed for immuno-
blotting. NIH3T3 cells stably expressing mSAMHD1 isoform 1 were
treated with speciﬁc inhibitors to CDK1 and CDK2 for 24 h and
then harvested for immunoblotting.
Knockdown of CDK1 and CDK2 in HEK293T cells by small interfering
RNA (siRNA)
HEK293T cells were seeded in 12-well plates (3105/well) at
24 h before transfection. Cells were transfected with 100 nM of
SMARTpool ON-TARGET plus siRNA speciﬁc for CDK1 (L003224),
CDK2 (L003236), or a scramble control (Dharmacon) using Trans-
IT TKO (Mirus) according to manufacturer’s protocol and two
rounds of transfection were performed as described (St Gelais
et al., 2014).
Virus stocks and infection assays
HIV-1 and MLV stocks were generated by transfecting HEK293T
cells as described (de Silva et al., 2012). Virus stocks wereharvested at 48 h post-transfection, and ﬁltered through 0.45 μM
ﬁlters. To generate luciferase reporter HIV-1 pseudotyped with
vesicular stomatitis virus G protein (HIV-luc/VSV-G), 10 μg pNL4-
3-luc E-Rþ and 4 μg pMD2-G (VSV-G) were used for transfection
(Connor et al., 1995). To generate GFP reporter HIV-1 pseudotyped
with VSV-G, 10 μg pHIV-CMV-GFP and 4 μg pMD2-G (VSV-G) were
used for transfection (Mulky et al., 2008). To generate GFP reporter
MLV (MLV-GFP/VSV-G), 10 μg pMIGR1, 5 μg pHIT60 and 4 μg
pVSV-G were used (Mulky et al., 2008). HIV-1 stocks and MLV-
GFP/VSV-G stocks were titrated with GHOST/X4/R5 cells (Wu et al.,
2002b) and HEK293T cells, respectively.
For HIV-1 luc/VSV-G infection, U937 cells were treated with
PMA and differentiated into non-dividing, macrophage-like cells
(Laguette et al., 2011a). U937 cells were seeded in 96-well plates
(1105 per well) and treated with PMA (30 ng/mL) for 20 h. Cells
were infected with HIV-1 at a multiplicity of infection (MOI) of
1 as described (Wang et al., 2009; Wu et al., 2002b). HIV-1
infection was determined by luciferase assays at 24 h post-
infection (St Gelais et al., 2014). For infections with HIV-GFP/
VSV-G and MLV-GFP/VSV-G, NIH3T3 stable cell lines were seeded
in 24-well plates (6104 cells/well). Cells were infected with MLV
at a MOI of 1. The infection was determined by detecting GFP-
positive cells with ﬂow cytometry (GUAVA mini 2.0) at 48 h post-
infection. The ﬂow cytometry data were analyzed by FlowJo.Quantitative PCR assays for MLV cDNA measurement
NIH3T3 stable cells were seeded in 24-well plates with 6104
cells per well each cell line. MLV stocks were treated with 60 U/mL
of TURBO DNase (Invitrogen, AM2238) for 30 min prior to infec-
tion assay. Cells were treated with control media, AZT (5 mM) for
30 min prior to MLV inoculation, and AZT was present for the
duration of MLV infection. Cells were harvest at 24 h post infection
for genomic DNA extraction using a DNeasy Blood & Tissue Kit
(QIAGEN) followed with the manufactory’s protocol.
The levels of late reverse transcription products and two one-
long-terminal-repeat (2-LTR) circles of MLV in infected NIH3T3 cells
were quantiﬁed by real-time quantitative PCR analysis using iQ™
SYBR
s
Green Supermix (BIO-RAD) followed protocol described in
(Wu and Roth, 2014). Genomic DNA (50 ng) from MLV-infected
NIH3T3 cells was used as the template for the detection of MLV late
reverse transcription products and cellular GAPDH, and 250 ng of
genomic DNA was used for the detection of MLV 2-LTR circles.
GAPDH was used as an internal normalization control for each
sample. The primers for genomic GAPDH detection are forward 5'-
AGT ACT GCA GAG CCC CCG-3', and reverse 5'-GAT GAT GGA GGA
CGT GAT GG -3' (Lofﬂer et al., 2007). For the detection of MLV late
reverse transcription products are: forward 5’-TTCTGTTCGCGCG
CTTC -3’, reverse 5’-TCC ACG ATT CGG ATG CAA AC-3’; for 2-LTR
circle are: forward 5'-CGC CAG TCC TCC GAT AGA-3' and reverse
5'- CTGTTCCTAACCTTGATCTGAACT-3'. The data were analyzed using
standard ΔΔCt method (Livak and Schmittgen, 2001).Intracellular dNTP measurement
For dNTP analysis and quantiﬁcation, cells were harvested and
lysed in iced cold 65% methanol, and vigorously vortexed for
2 min. Extracts were incubated at 95 °C for 3 min. Supernatants
were collected and dried in a speed vacuum. Samples were pro-
cessed for the single nucleotide incorporation assay as described
(Diamond et al., 2004).
F. Wang et al. / Virology 487 (2016) 273–284 283Statistical analysis
The data were analyzed by one-way ANOVA followed with
Dunnett’s test, or by t-test in Graphpad 5.0. The statistical sig-
niﬁcance was deﬁned as P o0.05.Acknowledgments
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